NUR 5213 Module 1 Drug Class Analysis Example

Why the Level Is Drawn When It Is: Aminoglycosides Explained From the Ribosome Outward, for the Nurses Who Give Them

Student Name

American College of Education

NUR5213: Advanced Pharmacology for Health Educators

Module 1 Assignment

Instructor Name

March 7, 2028

Why This Class

Aminoglycosides, chiefly gentamicin, tobramycin and amikacin, are used less often than they once were, which is exactly why nurses on the author's medical-surgical units handle them poorly. In a review of the past quarter's orders at the composite 280-bed community hospital where the author works as a nursing professional development specialist, 11 of 38 serum levels for once-daily gentamicin were drawn at the wrong time, most often immediately before the next dose out of habit from older dosing schedules. Nurses could recite that aminoglycosides harm the kidneys and ears but could not say why, and so could not tell which patients were most at risk or what to ask them. The class is a good example of how teaching from mechanism can turn scattered facts into judgment.

Mechanism of Action

Aminoglycosides kill bacteria by disrupting protein synthesis. They cross the outer membrane of gram-negative bacteria and are then carried across the inner membrane by a transport process that depends on oxygen. Inside the cell, they bind to the 30S subunit of the bacterial ribosome and cause it to misread messenger RNA, so that the bacterium produces faulty proteins. Some of these faulty proteins insert into the cell membrane and damage it, which lets more drug in and accelerates killing (Krause et al., 2016). Unlike many drugs that only slow bacterial growth, aminoglycosides are rapidly bactericidal.

Two features of this mechanism shape everything that follows. First, uptake depends on oxygen, so aminoglycosides have no useful activity against anaerobic bacteria and work poorly in acidic, low-oxygen sites such as abscesses. Second, killing depends on concentration: the higher the peak concentration relative to the amount needed to inhibit the organism, the faster and more complete the kill. Aminoglycosides also have a post-antibiotic effect, a period after levels fall during which bacterial growth remains suppressed.

From Mechanism to Dosing and Spectrum

Concentration-dependent killing and the post-antibiotic effect explain why most adult patients now receive aminoglycosides once daily rather than in divided doses. A single large dose produces a high peak for maximal killing, and the post-antibiotic effect covers the period when levels are low. The low trough before the next dose also matters for safety, as the next section explains. At one hospital that adopted a once-daily program using a fixed weight-based dose with an interval adjusted to kidney function and a single timed serum level interpreted with a nomogram, 1.2% of 2,184 patients developed nephrotoxicity, compared with a historical rate of about 3% to 5% at the same institution (Nicolau et al., 1995). That single timed level is the one nurses on the author's units were drawing at the wrong time: in extended-interval dosing, the level is taken at a set number of hours after the dose so that it can be plotted on the nomogram, not just before the next dose.

The mechanism also predicts the spectrum. Aminoglycosides act mainly against aerobic gram-negative bacteria such as Escherichia coli, Klebsiella and Pseudomonas. Against gram-positive organisms such as enterococci, they work poorly alone but well when combined with a drug that damages the cell wall, such as a beta-lactam, because the damaged wall lets the aminoglycoside in. That synergy is why an aminoglycoside may be added to penicillin or ampicillin for some serious gram-positive infections.

From Mechanism to Toxicity and Interactions

The same cellular uptake that kills bacteria explains the drug's toxicity in people. In the kidney, aminoglycosides are taken up by the cells of the proximal tubule, where they accumulate and damage the cells. Because this uptake is saturable, a single large daily dose loads the tubular cells less than the same total dose given in several smaller doses, and a low trough gives the cells time to clear the drug. Nephrotoxicity is usually nonoliguric and reversible, and it typically appears after several days of therapy as a rising creatinine. The kidney injury is predictable from the mechanism: more days, more drug held in tubular cells, and less time between doses to clear it.

In the inner ear, aminoglycosides damage the sensory hair cells of the cochlea and the vestibular system, and because these cells do not regenerate in humans, the damage is usually permanent (Selimoglu, 2007). Cochlear damage often begins with high-frequency hearing loss, which patients may not notice, and vestibular damage causes dizziness, unsteadiness and difficulty focusing during movement. Ringing in the ears or a feeling of fullness can be early warnings.

Interactions follow from these targets. Other drugs that harm the kidney, including vancomycin, loop diuretics, intravenous contrast and nonsteroidal anti-inflammatory drugs, add to the risk of kidney injury, and loop diuretics also add to the risk of ototoxicity. Dehydration concentrates the drug and increases both risks. Rarely, aminoglycosides can worsen neuromuscular weakness, a consideration in patients with myasthenia gravis.

The mechanism also identifies the patients at highest risk, which is more useful to a nurse than a general warning. Risk rises with longer courses, because tubular and hair cell exposure accumulates; with existing kidney disease and advanced age, because clearance is slower and the drug lingers; with dehydration or low blood pressure, because the kidneys receive less flow and concentrate the drug; and with concurrent nephrotoxic or ototoxic drugs. A small number of people carry an inherited variant in their mitochondrial DNA that makes the inner ear unusually sensitive to aminoglycosides, so that hearing loss can follow even a short course; a family history of hearing loss after antibiotics is worth asking about. A patient in the author's hospital who is 78, has a creatinine clearance of 35 mL per minute, is taking furosemide and is on day six of gentamicin carries several of these risks at once, and the nurse caring for that patient should be asking about hearing and balance every shift, not waiting for the patient to complain.

Monitoring and Teaching Points for Nurses

Monitoring follows directly from the mechanism. Nurses should know the time the level is due relative to the dose and draw it then, because the whole dosing strategy depends on it. They should review creatinine and urine output daily, recognizing that a rising creatinine after several days may require a change in interval or drug. They should check the medication list for other nephrotoxic drugs and ask the prescriber or pharmacist when two are combined. They should ask the patient each day about ringing in the ears, fullness, hearing change and dizziness, and watch for unsteadiness when the patient walks, since the patient may not volunteer these symptoms or connect them to the antibiotic. They should support hydration unless it is restricted.

For the author's teaching session, these points are organized as three questions a nurse asks before every dose: is the level due, and when; are the kidneys holding steady, and is anything else on the list hurting them; and has the patient noticed any change in hearing or balance? Each question comes from one step of the mechanism, and the session will end with nurses explaining that connection back, so that the questions become reasoning rather than a checklist.

References

Krause, K. M., Serio, A. W., Kane, T. R., & Connolly, L. E. (2016). Aminoglycosides: An overview. Cold Spring Harbor Perspectives in Medicine, 6(6), Article a027029. https://doi.org/10.1101/cshperspect.a027029

Nicolau, D. P., Freeman, C. D., Belliveau, P. P., Nightingale, C. H., Ross, J. W., & Quintiliani, R. (1995). Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrobial Agents and Chemotherapy, 39(3), 650-655. https://doi.org/10.1128/AAC.39.3.650

Selimoglu, E. (2007). Aminoglycoside-induced ototoxicity. Current Pharmaceutical Design, 13(1), 119-126. https://doi.org/10.2174/138161207779313731